MedTrace Logo

Humanistic Burden of (FSGS) Focal Segmental Glomerulosclerosis and IgAN (Immunoglobulin A Nephropathy)

NCT05200871 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 487

Last updated 2024-02-21

No results posted yet for this study

Summary

The aim of this observational study is to assess humanistic burden among adults and children/adolescents with FSGS and IgAN as well as the burden and impact for patient care-partners in six countries (United States \[US\], United Kingdom \[UK\], France, Germany, Italy and Spain).

Conditions

  • Focal Segmental Glomerulosclerosis
  • Immunoglobulin A Nephropathy

Sponsors & Collaborators

  • Travere Therapeutics, Inc.

    lead INDUSTRY

Principal Investigators

  • Leah Conley, MBA · Travere Therapeutics

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-02-05
Primary Completion
2023-10-31
Completion
2023-10-31

Countries

  • United States
  • Germany
  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05200871 on ClinicalTrials.gov